Pharmacology and clinical potential of oblimersen sodium in the treatment of chronic lymphocytic leukemia

Targeted inhibition of the Bcl-2 family of antiapoptotic proteins is expected to improve outcomes in chronic lymphocytic leukemia. Antisense oligonucleotides and small molecule inhibitors (BH3 mimetics) are two approaches that have been used to target Bcl-2 proteins. In this review, we summarize the experience with oblimersen sodium, an 18-base oligonucleotide targeting the first six codons of Bcl-2 mRNA, with particular focus on chronic lymphocytic leukemia. Despite evidence of improved outcomes in randomized trials of com- bination with chemoimmunotherapy, further development of this antisense approach has been slow, likely because of the clinical development of small molecule inhibitors.

[1]  H. Döhner,et al.  Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Advani,et al.  Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies , 2011, Investigational New Drugs.

[3]  A. Berrebi,et al.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.

[4]  J. Gribben,et al.  5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Jagannath,et al.  Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma , 2009, Leukemia & lymphoma.

[6]  B. Leber,et al.  Phase II multicenter study of oblimersen sodium, a Bcl‐2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B‐cell non‐Hodgkin lymphoma , 2008, British journal of haematology.

[7]  R. Bociek,et al.  Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  H. Pehamberger,et al.  Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Tolcher,et al.  A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  K. Rai,et al.  Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[12]  C. Bloomfield,et al.  Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Gleave,et al.  A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer , 2005, Clinical Cancer Research.

[14]  Arjan,et al.  High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma , 2005, Journal of Clinical Pathology.

[15]  T. Kuwana,et al.  BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. , 2005, Molecular cell.

[16]  F. Jin,et al.  Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts. , 2004, Molecular cancer therapeutics.

[17]  T. McDonnell,et al.  MCL-1 expression in B-cell non-Hodgkin's lymphomas. , 2004, Human pathology.

[18]  A. Tolcher,et al.  A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer , 2004, Clinical Cancer Research.

[19]  P. Gaulard,et al.  Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). , 2003, Blood.

[20]  M. Caligiuri,et al.  Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. , 2003, Blood.

[21]  T. McDonnell,et al.  Expression of Mcl‐1 in mantle cell lymphoma is associated with high‐grade morphology, a high proliferative state, and p53 overexpression , 2003, The Journal of pathology.

[22]  S. Korsmeyer,et al.  Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. , 2002, Cancer cell.

[23]  A. Gillum,et al.  Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. , 2002, Antisense & nucleic acid drug development.

[24]  S. Barrans,et al.  Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. , 2002, Blood.

[25]  S. Korsmeyer,et al.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. , 2001, Molecular cell.

[26]  Xiaodong Wang,et al.  Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.

[27]  R. Gascoyne,et al.  Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  Y Li,et al.  [Mitochondria and apoptosis]. , 2000, Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine].

[29]  Xiaodong Wang,et al.  Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors , 1998, Cell.

[30]  S. Korsmeyer,et al.  Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis , 1998, The EMBO journal.

[31]  M. Piris,et al.  Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J C Reed,et al.  Bax directly induces release of cytochrome c from isolated mitochondria. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J C Reed,et al.  IAPs block apoptotic events induced by caspase‐8 and cytochrome c by direct inhibition of distinct caspases , 1998, The EMBO journal.

[34]  Yi-Te Hsu,et al.  Movement of Bax from the Cytosol to Mitochondria during Apoptosis , 1997, The Journal of cell biology.

[35]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[36]  R. Gottlieb,et al.  Bcl-2 and the Outer Mitochondrial Membrane in the Inactivation of Cytochrome c during Fas-mediated Apoptosis* , 1997, The Journal of Biological Chemistry.

[37]  Xiaodong Wang,et al.  Apaf-1, a Human Protein Homologous to C. elegans CED-4, Participates in Cytochrome c–Dependent Activation of Caspase-3 , 1997, Cell.

[38]  Y. Hsu,et al.  Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[39]  C. Pepper,et al.  REGULATION OF CLINICAL CHEMORESISTANCE BY bcl‐2 AND BAX ONCOPROTEINS IN B‐CELL CHRONIC LYMPHOCYTIC LEUKAEMIA , 1996, British journal of haematology.

[40]  Guido Kroemer,et al.  Mitochondria and programmed cell death: back to the future , 1996, FEBS letters.

[41]  G. Kroemer,et al.  Bcl-2 inhibits the mitochondrial release of an apoptogenic protease , 1996, The Journal of experimental medicine.

[42]  T. McDonnell,et al.  Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. , 1996, Journal of immunology.

[43]  M. Castedo,et al.  Mitochondrial control of nuclear apoptosis , 1996, The Journal of experimental medicine.

[44]  P. Johnson,et al.  Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. , 1994, Oncogene.

[45]  J C Reed,et al.  Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. , 1990, Cancer research.

[46]  S. Korsmeyer,et al.  bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation , 1989, Cell.

[47]  J. Sklar,et al.  Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation , 1986, Cell.

[48]  S. Korsmeyer,et al.  Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around Jh on chromosome 14 and near a transcriptional unit on 18 , 1985, Cell.

[49]  P. Nowell,et al.  Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. , 1984, Science.

[50]  T. McDonnell,et al.  Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. , 1996, Leukemia.

[51]  J. Rouault,et al.  Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. , 1994, Blood.

[52]  John Calvin Reed,et al.  Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. , 1993, Antisense research and development.

[53]  John Calvin Reed,et al.  bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. , 1993, Blood.